302: Ignite Session 1B

Presentations:

• 1:00 PM – 1:05 PM Eastern Time

  Delayed Referral of Female Rheumatoid Arthritis Patients: Where Are We Now? A Study Spanning Three Decades
  

  Ignite Speaker: Bastiaan van Dijk, MD, MSc – Leiden University Medical Centre (LUMC)
• 1:05 PM – 1:10 PM Eastern Time

  What Drives Racial Disparities in Gout in the USA? – Population-Based, Sex-Specific, Casual Mediation Analysis
  

  Ignite Speaker: Natalie McCormick, PhD, MSc – Massachusetts General Hospital
• 1:10 PM – 1:15 PM Eastern Time

  Lack of Racial and Ethnic Diversity in Clinical Trials of Psoriatic Arthritis
  

  Ignite Speaker: Niti Goel, MD – TrialSpark, Duke University
• 1:15 PM – 1:20 PM Eastern Time

  Documentation of Social Determinants of Health Among Individuals with Systemic Rheumatic and Musculoskeletal Diseases
  

  Ignite Speaker: Sciaska Ulysse, BA – Brigham and Women's Hospital
• 1:20 PM – 1:25 PM Eastern Time

  Application of the Consolidated Framework for Implementation Research (CFIR) to Study Top-Performing Practices in the RISE Registry
  

  Ignite Speaker: Lindsay Jacobsohn, BA – University of California, San Francisco
• 1:25 PM – 1:30 PM Eastern Time

  Development and Pilot Implementation of a Predictive Model to Identify Visits Appropriate for Telehealth
  

  Ignite Speaker: David Leverenz, MD – Duke University
• 1:30 PM – 1:35 PM Eastern Time

  Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
  

  Ignite Speaker: Laura C. Coates, MD, PhD – University of Oxford
• 1:35 PM – 1:40 PM Eastern Time

  Characteristics Associated with a Positive PEST Screening Among Patients with Psoriasis Without a Diagnosis of Psoriatic Arthritis: Results from the Global Psoriasis and Beyond Study
  

  Ignite Speaker: Alexis Ogdie, MD – University of Pennsylvania
• 1:40 PM – 1:45 PM Eastern Time

  Factors Influencing Visit Preference in Patients with Rheumatic Diseases: A Qualitative Study
  

  Ignite Speaker: Kiara Aaron, MS – UAB School of Public Health
• 1:45 PM – 1:50 PM Eastern Time

  Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes - 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis
  

  Ignite Speaker: Frank Behrens, MD – Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Germany